2026-04-14T03:31:21Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4635822025-02-25T17:08:44Zcom_2072_98col_2072_378192

Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection Pleguezuelos, Patricia Sibila, Marina Cuadrado Matías, Raúl López-Jiménez, Rosa Pérez, Diego Huerta, Eva Pérez, Mónica Correa-Fiz, Florencia Mancera-Gracia, José Carlos Taylor, Lucas P. Borowski, Stasia Saunders, Gillian Segalés Coma, Joaquim López-Soria, Sergio Balasch, Monica Swine Porcine circovirus 2 Porcine circovirus 2-systemic disease Mycoplasma hyopneumoniae Porcine respiratory disease complex Trivalent vaccine Efficacy Four studies under preclinical and clinical conditions were performed to evaluate the efficacy of a new trivalent vaccine against Porcine circovirus 2 (PCV-2) infection. The product contained inactivated PCV-1/PCV-2a (cPCV-2a) and PCV-1/PCV-2b (cPCV-2b) chimeras, plus M. hyopneumoniae inactivated cell-free antigens, which was administered to piglets in a two-dose regime at 3 days of age and 3 weeks later. The overall results of preclinical and clinical studies show a significant reduction in PCV-2 viraemia and faecal excretion, and lower histopathological lymphoid lesions and PCV-2 immunohistochemistry scores in vaccinated pigs when compared to non-vaccinated ones. Furthermore, in field trial A, a statistically significant reduction in the incidence of PCV-2-subclinical infection, an increase in body weight from 16 weeks of age to slaughterhouse and an average daily weight gain over the whole period (from 3 days of age to slaughterhouse) was detected in the vaccinated group when compared to the non-vaccinated one. Circulation of PCV-2a in field trial A, and PCV-2b plus PCV-2d in field trial B was confirmed by virus sequencing. In conclusion, a double immunization with a cPCV-2a/cPCV-2b/ M. hyopneumoniae vaccine was efficacious against PCV-2 infection by reducing the number of histopathological lymphoid lesions and PCV-2 detection in tissues, serum, and faeces, as well as reducing losses in productive parameters. 2022 Article https://ddd.uab.cat/record/266110 urn:10.3390/vaccines10081234 urn:oai:ddd.uab.cat:266110 urn:pmcid:PMC9414577 urn:pmc-uid:9414577 urn:pmid:36016122 urn:oai:pubmedcentral.nih.gov:9414577 urn:oai:egreta.uab.cat:publications/056ae918-fb8c-4d7d-8d4d-3b5f84828512 urn:scopus_id:85137381432 eng Vaccines (Basel) ; Vol. 10 (august 2022) open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf